Company Overview - Xencor Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies for treating asthma, allergic diseases, autoimmune diseases, and cancer [4] Investment Sentiment - Bank of America raised its price target for Xencor to $20 from $17 while maintaining a Neutral rating, indicating a positive outlook for the stock [1] - Barclays also increased its price target for Xencor from $23 to $26 and maintained an Overweight rating, reflecting a favorable adjustment in valuations across the biotech sector [3] Industry Trends - The biotech sector is experiencing a resurgence due to stabilizing factors such as positive data catalysts, increased large-cap M&A and licensing activity, better access to capital, and limited impact from drug price regulations [2] - Despite the positive developments, there is caution regarding the long-term sustainability of the recovery in the biotech industry [2]